Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Viramune in Progressive HIV Disease
NCT00002166Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of nevirapine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Safety and Tolerability of Viramune at 32 weeks. Status: completed.
02
Drugs
nevirapine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002166.